STOPPIT-3
Research type
Research Study
Full title
A Randomised Placebo-Controlled Trial of Antenatal Corticosteroids for Planned Birth in Twins: STOPPIT-3
IRAS ID
1004166
Contact name
Sarah Stock
Contact email
Sponsor organisation
University of Edinurgh
Eudract number
2021-002876-38
ISRCTN Number
ISRCTN12345678
Clinicaltrials.gov Identifier
Research summary
This study aims to find out if the drug antenatal corticosteroids (ACS) given to women with a twin pregnancy prior to a planned birth of twins reduces breathing difficulties in the twin babies.
Twin pregnancies have a higher risk of complications than a singleton pregnancy. Women with a twin pregnancy are at risk of having a baby preterm (before their due date) and babies born prematurely have increased risk of health problems and are more likely to require admission to the neonatal unit.
We hope to involve a large number of NHS Centres throughout the UK. We will ask women with a twin pregnancy who have a planned birth after 35 weeks of pregnancy if they will participate in the study. Women who agree to take part in the study will be treated with either ACS or a placebo (dummy drug). These will be administered by injection prior to the planned birth around 36 weeks in monochorionic twins (shared placenta) and 37 weeks in dichorionic twins (a placenta each).
We will look at the number of babies who are born (or die) in each group and look at the complications that happen to babies when we compare the two groups. If we find that the use of ACS improves outcomes in twin babies it could be used in the NHS straight away. If it works we hope it will reduce healthcare costs.REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
22/WM/0018
Date of REC Opinion
15 Feb 2022
REC opinion
Further Information Favourable Opinion